Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments... Show more
Industry Biotechnology
A.I.dvisor tells us that RNTX and PRLD have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RNTX and PRLD's prices will move in lockstep.
| Ticker / NAME | Correlation To RNTX | 1D Price Change % | ||
|---|---|---|---|---|
| RNTX | 100% | +0.53% | ||
| PRLD - RNTX | 33% Poorly correlated | -1.71% | ||
| CBIO - RNTX | 27% Poorly correlated | -0.26% | ||
| SMMT - RNTX | 26% Poorly correlated | +3.24% | ||
| PDSB - RNTX | 25% Poorly correlated | -6.47% | ||
| PRTA - RNTX | 25% Poorly correlated | -1.00% | ||
More | ||||
RNTX moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend. In 27 of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
RNTX broke above its upper Bollinger Band on September 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RNTX's RSI Indicator exited the oversold zone, 35 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on September 11, 2026. You may want to consider a long position or call options on RNTX as a result. In 78 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for RNTX just turned positive on August 07, 2026. Looking at past instances where RNTX's MACD turned positive, the stock continued to rise in 36 of 40 cases over the following month. The odds of a continued upward trend are 90%.
Following a +14.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNTX advanced for three days, in 167 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 109 of 127 cases where RNTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.640) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (427.627).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. RNTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.